referring to the chemical name for Lilly's drugs. Novo Nordisk's treatments still appeared on the FDA's shortage list on Thursday. Lilly has started selling vials of the lowest dose of Zepbound in ...

near another multibillion-dollar manufacturing site that produces tirzepatide, the active ingredient in its blockbuster GLP-1 drugs, Mounjaro and Zepbound. Eli Lilly described the new center as a ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources ...

Eli Lilly’s Mounjaro was added to the FDA’s drug shortage database in 2022, while Zepbound was added this April. Eli Lilly did not immediately respond to a request for comment from Quartz.

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ...